{"doi":"10.1002/ijc.35411","title":"Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study","abstract":"<jats:title>Abstract</jats:title><jats:p>To prevent thrombosis in patients with polycythemia vera (PV), achieving a complete hematologic response (CHR) is highly recommended in practice. In addition, a reduced <jats:italic>JAK2</jats:italic> V617F mutation burden is expected to have a disease‐modifying effect, and its molecular response (MR) is currently of significant interest. This study aimed to assess the association between CHR and MR in patients with PV following treatment with ropeginterferon alfa‐2b. This phase 2, single‐arm, open‐label, investigator‐initiated trial was conducted at 16 sites in South Korea. Ninety‐nine patients were treated with ropeginterferon alfa‐2b subcutaneously every 2 weeks, at doses of 250 μg (week 1), 350 μg (week 3), and 500 μg (week 5), until week 48. CHRs were 27% (25/94), 46% (40/87), 56% (47/84), and 63% (51/81) at 12, 24, 36, and 48 weeks, respectively. The MR rates were 32% (28/88), 36% (29/81), 49% (38/77), and 57% (42/74) at 12, 24, 36, and 48 weeks, respectively. The Phi Coefficient for the association between CHR and MR was 0.6146 (<jats:italic>p</jats:italic> &lt; .0001) at 48 weeks. In the subgroup analysis, patients with hydroxyurea resistance or intolerance, and those who were hydroxyurea‐naïve, had similar results in terms of the CHR. In conclusion, CHR and MR were observed to be associated in patients with PV treated with ropeginterferon.</jats:p>","journal":"International Journal of Cancer","year":2025,"id":607968,"datarank":0.3958585994422889,"base_score":2.639057329615259,"endowment":2.639057329615259,"self_citation_contribution":0.3958585994422889,"citation_network_contribution":0.0,"self_endowment_contribution":0.3958585994422889,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1561208,"name":"Sung‐Soo Yoon","orcid":null,"position":1,"is_corresponding":false},{"id":1561209,"name":"Deok‐Hwan Yang","orcid":null,"position":2,"is_corresponding":false},{"id":1561210,"name":"Gyeong‐Won Lee","orcid":null,"position":3,"is_corresponding":false},{"id":1561211,"name":"Sang Kyun Sohn","orcid":null,"position":4,"is_corresponding":false},{"id":1561212,"name":"Ho‐Jin Shin","orcid":null,"position":5,"is_corresponding":false},{"id":1561215,"name":"Sung Hwa Bae","orcid":null,"position":6,"is_corresponding":false},{"id":724052,"name":"Chul Won Choi","orcid":"0000-0002-3032-4239","position":7,"is_corresponding":false},{"id":946381,"name":"Eun‐Ji Choi","orcid":"0000-0001-8222-0311","position":8,"is_corresponding":false},{"id":1430800,"name":"June‐Won Cheong","orcid":"0000-0002-1744-0921","position":9,"is_corresponding":false},{"id":1561219,"name":"Soo‐Mee Bang","orcid":null,"position":10,"is_corresponding":false},{"id":1561220,"name":"Joon Seong Park","orcid":null,"position":11,"is_corresponding":false},{"id":1561221,"name":"Suk Joong Oh","orcid":null,"position":12,"is_corresponding":false},{"id":1063838,"name":"Yong Park","orcid":"0000-0001-7909-6639","position":13,"is_corresponding":false},{"id":1554854,"name":"Young Hoon Park","orcid":"0000-0003-4516-7990","position":14,"is_corresponding":false},{"id":288958,"name":"Sung‐Eun Lee","orcid":"0000-0001-7690-9956","position":15,"is_corresponding":false},{"id":1561207,"name":"Seug Yun Yoon","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study","abstract":"<jats:title>Abstract</jats:title><jats:p>To prevent thrombosis in patients with polycythemia vera (PV), achieving a complete hematologic response (CHR) is highly recommended in practice. In addition, a reduced <jats:italic>JAK2</jats:italic> V617F mutation burden is expected to have a disease‐modifying effect, and its molecular response (MR) is currently of significant interest. This study aimed to assess the association between CHR and MR in patients with PV following treatment with ropeginterferon alfa‐2b. This phase 2, single‐arm, open‐label, investigator‐initiated trial was conducted at 16 sites in South Korea. Ninety‐nine patients were treated with ropeginterferon alfa‐2b subcutaneously every 2 weeks, at doses of 250 μg (week 1), 350 μg (week 3), and 500 μg (week 5), until week 48. CHRs were 27% (25/94), 46% (40/87), 56% (47/84), and 63% (51/81) at 12, 24, 36, and 48 weeks, respectively. The MR rates were 32% (28/88), 36% (29/81), 49% (38/77), and 57% (42/74) at 12, 24, 36, and 48 weeks, respectively. The Phi Coefficient for the association between CHR and MR was 0.6146 (<jats:italic>p</jats:italic> &lt; .0001) at 48 weeks. In the subgroup analysis, patients with hydroxyurea resistance or intolerance, and those who were hydroxyurea‐naïve, had similar results in terms of the CHR. In conclusion, CHR and MR were observed to be associated in patients with PV treated with ropeginterferon.</jats:p>","is_dataset_classified":null,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40087986","pmcid":"PMC12141981","openalex_id":"https://openalex.org/W4408490151","authors":[],"funders":[{"funder_name":"PharmaEssentia, Taiwan","grant_id":"","title":null},{"funder_name":"PharmaEssentia, Taiwan","grant_id":"","title":null}],"total_grants":2,"fwci":9.4902,"citation_percentile":0.98480147,"influential_citations":0,"citation_trend":[{"year":2025,"count":8},{"year":2026,"count":4}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.35411","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.35411","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.35411","host_type":"publisher"},{"url":"https://doi.org/10.1002/ijc.35411","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40087986","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12141981","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12141981","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12141981?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Myeloproliferative Neoplasms: Diagnosis and Treatment","Eosinophilic Disorders and Syndromes","Kruppel-like factors research","Humans","Polycythemia Vera","Polyethylene Glycols","Interferon-alpha","Male","Female","Middle Aged","Recombinant Proteins","Interferon alpha-2","Adult","Prospective Studies","Aged","Janus Kinase 2","Treatment Outcome","Mutation"],"mesh_terms":["Interferon alpha-2","Adult","Aged","Female","Humans","Male","Middle Aged","Mutation","Polycythemia Vera","Polyethylene Glycols","Prospective Studies","Recombinant Proteins","Treatment Outcome","Interferon-alpha","Janus Kinase 2"],"keywords":["Medicine","Polycythemia vera","Internal medicine","Gastroenterology","Thrombosis","Prospective cohort study","Surgery","Association","MR","Chr","Ropeginterferon Alfa‐2b"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T07:17:24.497014Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}